Aviceda Therapeutics
Biotechnology, 1 Broadway Ste 14, Cambridge, Massachusetts, 02142, United States, 51-200 Employees
Who is AVICEDA THERAPEUTICS
The Future of Glyco-therapeutics Aviceda Therapeutics is a disruptive clinical-stage biotech company focused on the next generation of immuno-modulators by harnessing the power of glycobi...
Read More
-
Headquarters: 1 Broadway Ste 14, Cambridge, Massachusetts, 02142, United States
-
Date Founded: 2018
-
Employees: 51-200
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 5122
Does something look wrong? Fix it. | View contact records from AVICEDA THERAPEUTICS
Aviceda Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Aviceda Therapeutics
Answer: Aviceda Therapeutics's headquarters are located at 1 Broadway Ste 14, Cambridge, Massachusetts, 02142, United States
Answer: Aviceda Therapeutics's official website is https://avicedarx.com
Answer: Aviceda Therapeutics's revenue is $1 Million to $5 Million
Answer: Aviceda Therapeutics's SIC: 5122
Answer: Aviceda Therapeutics has 51-200 employees
Answer: Aviceda Therapeutics is in Biotechnology
Answer: Aviceda Therapeutics contact info: Phone number: Website: https://avicedarx.com
Answer: The Future of Glyco-therapeutics Aviceda Therapeutics is a disruptive clinical-stage biotech company focused on the next generation of immuno-modulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly using a propriety HALOS platform Technology. Aviceda is developing glyco-immuno therapeutics targeting devastating ocular and systemic degenerative, fibrotic, and immuno-inflammatory diseases. A combination of cutting-edge technologies and deep biological insights form Avicedas engine of transformative product creation. Aviceda has combined the power of our glycobiology and glycochemistry platform with our proprietary nanoparticle technology (HALOS) to engineer transformative disease modifying medicines. Using our cell-based high-throughput screening (HTS) platform, we can rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. Optimized ligands are tethered to our modular biodegradable nanoparticles using high precision conjugation chemistry to form biologically stable linkages. Our GCT nanoparticles are designed for optimal therapeutic durability and maximum therapeutic efficacy while utilizing the most effective route of administration. Avicedas platform is highly adaptable, enabling the development of a broad spectrum of therapeutics for immuno-inflammatory indications with large unmet medical needs.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month